PMID- 37356522
OWN - NLM
STAT- MEDLINE
DCOM- 20230828
LR  - 20230830
IS  - 1096-0953 (Electronic)
IS  - 0013-9351 (Linking)
VI  - 233
DP  - 2023 Sep 15
TI  - Targeted therapy of breast tumor by PLGA-based nanostructures: The versatile 
      function in doxorubicin delivery.
PG  - 116455
LID - S0013-9351(23)01259-8 [pii]
LID - 10.1016/j.envres.2023.116455 [doi]
AB  - Breast carcinoma is a molecularly diverse illness, and it is among the most 
      prominent and often reported malignancies in female across the globe. Surgical 
      intervention, chemotherapy, immunotherapy, gene therapy, and endocrine treatment 
      are among the currently viable treatment options for the carcinoma of breast. 
      Chemotherapy is among the most prevalent cancer management strategy. Doxorubicin 
      (DOX) widely employed as a cytostatic medication for the treatment of a variety 
      of malignancies. Despite its widespread acceptance and excellent efficacy against 
      an extensive line up of neoplasia, it has a variety of shortcomings that limit 
      its therapeutic potential in the previously mentioned indications. Employment of 
      nanoparticulate systems has come up as a unique chemo medication delivery 
      strategy and are being considerably explored for the amelioration of breast 
      carcinoma. Polylactic-co-glycolic acid (PLGA)-based nano systems are being 
      utilized in a number of areas within the medical research and medication delivery 
      constitutes one of the primary functions for PLGA given their inherent 
      physiochemical attributes, including their aqueous solubility, biocompatibility, 
      biodegradability, versatility in formulation, and limited toxicity. Herein along 
      with the different application of PLGA-based nano formulations in cancer therapy, 
      the present review intends to describe the various research investigations that 
      have been conducted to enumerate the effectiveness of DOX-encapsulated PLGA 
      nanoparticles (DOX-PLGA NPs) as a feasible treatment option for breast cancer.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Sonam Dongsar, Tenzin
AU  - Sonam Dongsar T
AD  - Department of Pharmaceutics, School of Pharmaceutical Education and Research, 
      Jamia Hamdard, New Delhi, 110062, India.
FAU - Tsering Dongsar, Tenzin
AU  - Tsering Dongsar T
AD  - Department of Pharmaceutics, School of Pharmaceutical Education and Research, 
      Jamia Hamdard, New Delhi, 110062, India.
FAU - Molugulu, Nagashekhara
AU  - Molugulu N
AD  - School of Pharmacy, Monash University, Bandar Sunway, Jalan Lagoon Selatan, 
      47500, Malaysia.
FAU - Annadurai, Sivakumar
AU  - Annadurai S
AD  - Department of Pharmacognosy, College of Pharmacy, King Khalid University, Abha 
      62529, Saudi Arabia.
FAU - Wahab, Shadma
AU  - Wahab S
AD  - Department of Pharmacognosy, College of Pharmacy, King Khalid University, Abha 
      62529, Saudi Arabia.
FAU - Gupta, Neelima
AU  - Gupta N
AD  - Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, Madhya Pradesh, 
      470003, India.
FAU - Kesharwani, Prashant
AU  - Kesharwani P
AD  - Department of Pharmaceutics, School of Pharmaceutical Education and Research, 
      Jamia Hamdard, New Delhi, 110062, India; Department of Pharmacology, Saveetha 
      Dental College, Saveetha Institute of Medical and Technical Sciences, Saveetha 
      University, Chennai, India. Electronic address: prashantdops@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230624
PL  - Netherlands
TA  - Environ Res
JT  - Environmental research
JID - 0147621
RN  - 0 (Glycols)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Female
MH  - Humans
MH  - Glycols/therapeutic use
MH  - Polylactic Acid-Polyglycolic Acid Copolymer/therapeutic use
MH  - Cell Line, Tumor
MH  - Doxorubicin/therapeutic use
MH  - *Breast Neoplasms/drug therapy
MH  - *Nanostructures
MH  - *Nanoparticles
OTO - NOTNLM
OT  - Breast cancer
OT  - Chemotherapy
OT  - Doxorubicin
OT  - Nano systems
OT  - Polylactic-co-glycolic acid
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/06/26 00:41
MHDA- 2023/08/28 06:42
CRDT- 2023/06/25 19:13
PHST- 2023/05/21 00:00 [received]
PHST- 2023/06/15 00:00 [revised]
PHST- 2023/06/17 00:00 [accepted]
PHST- 2023/08/28 06:42 [medline]
PHST- 2023/06/26 00:41 [pubmed]
PHST- 2023/06/25 19:13 [entrez]
AID - S0013-9351(23)01259-8 [pii]
AID - 10.1016/j.envres.2023.116455 [doi]
PST - ppublish
SO  - Environ Res. 2023 Sep 15;233:116455. doi: 10.1016/j.envres.2023.116455. Epub 2023 
      Jun 24.